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Abstract 
Background: Chronic thromboembolic pulmonary hypertension (CTEPH) can cause 
right heart failure. A concomitant psychiatric disorder (PD) is thought to increase the 
risk of acute pulmonary thromboembolism; however, whether PDs are associated with 
deterioration in CTEPH pathophysiology is unclear. In this study, we evaluated the 
clinical characteristics and prognoses in patients with CTEPH and a co-existing PD. 
Methods: We retrospectively identified 229 consecutive patients (mean age 58.7 ± 12.5 
years; 160 women) with CTEPH and categorized them according to whether they had a 
PD (PD group; n = 22, 9.7%) or not (non-PD group; n = 207, 90.3%). We compared the 
clinical characteristics, respiratory function, hemodynamics, and clinical courses in the 
two groups. Those in the PD group had significantly lower exercise tolerance compared 
to the non-PD group (6-minute walk test, 309.5 ± 89.5 m vs. 369.4 ± 97.9 m, p = 0.008, 
percent vital capacity 85.5% ± 17.3% vs. 96.0% ± 15.5%, p = 0.003), and partial 
pressure of oxygen (PaO2) (54.4 ± 8.6 mmHg vs. 59.3 ± 10.7 mmHg, p = 0.039). Three-
year survival was significantly poorer in the PD group compared to the non-PD group 
(66.1% vs 89.7%, p = 0.0026, log-rank test), particularly in patients who underwent 
surgery (62.2% vs 89.5%, p < 0.001, log-rank test). 
Conclusions: A concomitant PD was associated with low exercise tolerance and 
impaired respiratory function in patients with CTEPH and predicted poor survival, 
especially in those who underwent a pulmonary endarterectomy.  
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Chronic thromboembolic pulmonary hypertension (CTEPH) is a type of 
pulmonary hypertension (PH) caused by chronic obstruction of the pulmonary arteries 
and secondary changes in the microcirculatory bed of the lungs.1,2 The condition 
sometimes results in a progressive increase in pulmonary vascular resistance (PVR) and 
pulmonary artery pressure (PAP) with the development of right heart failure. The 
incidence and prevalence of CTEPH has been gradually increasing but may be 
underestimated because of its nonspecific symptoms and variable disease course.3  
Pulmonary endarterectomy (PEA) is currently considered the definitive 
treatment for CTEPH. Medical therapies for pulmonary arterial hypertension, including 
guanylate cyclase agonists, phosphodiesterase-5 inhibitors, endothelin receptor 
antagonists, and prostacyclin analogs, have been developed for patients who are not 
candidates for surgery.4,5 These drugs have improved the survival rate in patients with 
CTEPH.4,6 Balloon pulmonary angioplasty is also used to improve pulmonary 
hemodynamics, right heart function, exercise tolerance, and other symptoms in these 
patients,7,8 and has steadily improved prognoses in the short and long term.9,10 
However, other complications can impact CTEPH prognoses. In routine 
clinical practice, it is not uncommon to encounter patients with CTEPH who also have a 
psychiatric disorder (PD). Moreover, it has been reported that patients on oral 
antipsychotic medication are more likely to develop a pulmonary thromboembolism.11 
Oral antidepressants and antipsychotics increase the risk of acute thromboembolism 
themselves, and the use of these agents has been mentioned among the risk factors for 
thrombosis.12,13 Furthermore, patients with chronic heart failure have been reported to 
have a significantly worse prognosis if they have concomitant depression.14 However, 
the pathophysiology and prognoses in patients with a pulmonary thromboembolism, 
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including CTEPH, and a chronic PD are not well defined.  
The aim of the present study was to investigate the clinical characteristics and 
prognoses in patients with CTEPH and a concomitant PD. 
 
Methods 
Study Population 
This retrospective, single-centered, observational study included 229 
consecutive patients with CTEPH confirmed by right heart catheterization and chronic 
thromboembolism findings between January 2000 and March 2017. No exclusion 
criteria were applied. The study was approved by the ethics committee of Chiba 
University, Japan (approval number 2584). Written informed consent was obtained from 
all patients who were enrolled since 2009, when this requirement became mandatory 
(approval number 826). 
 
Background Patient Characteristics 
Many of the patients enrolled in the study had visited our hospital complaining 
of shortness of breath or palpitation during exercise. We performed echocardiography as 
an initial test to detect PH. If findings indicating PH were present, such as increased 
pressure across the tricuspid valve or increased right-sided filling pressure causing 
displacement of the left ventricle, right heart catheterization was performed to confirm 
the presence of PH. Ventilation/perfusion scans, pulmonary angiography, and contrast-
enhanced computed tomography were performed to confirm the presence of pulmonary 
thromboemboli and exclude other types of PH. A diagnosis of CTEPH was confirmed 
when chronic occlusion of the pulmonary arteries by organized thrombi leading to PH 
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was present despite anticoagulation therapy for more than 3 months. Surgical treatment 
included PEA only. The observation period was calculated from the date of the first 
right heart catherization at our institution until death or the end of the study period. 
Patients with a history of psychiatric attendances and ongoing use of 
psychiatric medication were defined as having a PD. Sex, age, smoking history, and use 
of oral antipsychotics were recorded at the time of diagnosis. Subjective symptoms were 
categorized according to the World Health Organization (WHO) functional 
classification for PH. The central disease score was calculated by adding the number of 
abnormal central portions, defined as proximal to the segmental branches and divided 
into four portions.15 The Jamieson classification (types I–IV) according to the location 
and morphology of thromboembolic and vascular wall diseases at the time of surgery 
was also used.16 Although the Jamieson classification could not be estimated 
preoperatively, it is important for the proper judgment of surgery adaptation and 
prognosis estimation.17 
 
Blood Tests 
We collected data on cardiac loads and coagulation by measuring brain 
natriuretic peptide, D-dimer, coagulation factor VIII, fibrinogen, protein C, and lupus 
anticoagulant levels for all patients. 
 
Right Heart Catheterization 
A 7.5 French Swan-Ganz thermodilution catheter (Edwards Lifesciences, 
Irvine, CA, USA) was inserted using a jugular approach. Pressure was measured at the 
superior vena cava, right atrium, right ventricle, and main pulmonary artery. Pulmonary 
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artery wedge pressure (PAWP) was measured at the end-expiration point. The zero point 
was defined as mid-thoracic. Cardiac output (CO) was determined using the 
thermodilution method by averaging a minimum of three measurements. Left-to-right 
shunting was ruled out using oximetry. PVR was calculated in Wood units using the 
following equation: 
PVR = [mean PAP (mPAP) − PAWP]/CO.  
 
Pulmonary Angiography 
Digital subtraction angiography using a 7 French Berman angiographic balloon 
catheter (Teleflex, Wayne, PA, USA) was performed to confirm typical findings of 
chronic embolisms including pouch defects, webs and bands, intimal irregularities, 
abrupt narrowing, and complete obstruction. 
 
Six-Minute Walk Test 
The 6-minute walk test (6MWT) was conducted in accordance with the 
American Thoracic Society guidelines,18 whereby patients are requested to walk as far 
as possible in 6 minutes. The heart rate, Borg scale score, and oxygen saturation were 
recorded before and after the test and the distance walked was noted. The test was 
performed with oxygen inhalation use in patients requiring home oxygen therapy. 
 
Spirometry 
Spirometry was performed using a Chestac-8900 (Nihon Kohden, Tokyo, 
Japan) or Fudac-60 (Fukuda Denshi, Tokyo, Japan) device following the Japanese 
Respiratory Society guidelines, which are based on the American Thoracic Society 
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guidelines.19 Vital capacity (VC), forced VC, and forced expiratory volume in 1 second 
were measured using standard techniques. Diffusing capacity for carbon monoxide 
(DLCO) and DLCO/alveolar ventilation (VA) values were measured by the helium 
dilution and single-breath methods. These data were calculated as percentages of 
predicted values. 
 
Statistical Analysis 
The results are expressed as the mean ± standard deviation. The means of 
continuous variables were compared between groups using the Mann-Whitney U test 
and the proportions of categorical variables were compared using the chi-square test. 
Univariate regression analysis was used to compare two parameters where appropriate. 
Univariate and multivariate Cox proportional hazards models were also used to identify 
factors contributing to poor long-term outcomes. Survival was estimated using the 
Kaplan-Meier method, and survival estimates were compared using the log-rank test. 
All statistical analyses were performed using JMP Pro 13 software (SAS Institute Inc., 
Cary, NC, USA). The threshold for statistical significance was set at p < 0.05. 
 
Results 
Patient Characteristics 
Table 1 shows the patient characteristics at baseline. The study population 
comprised 229 consecutive patients (mean age 58.7 ± 12.5 years; 160 women) with 
CTEPH confirmed by right heart catheterization and pulmonary angiography. One-
hundred-thirty (56.8%) of the 229 patients underwent PEA. The Jamieson classification 
after PEA was I in 81 patients, II in 32, III in 14, IV in 1, and unknown in 2 cases. The 
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remaining 99 patients in the study (43.2%) received medication and/or underwent 
balloon pulmonary angioplasty (BPA; n = 29, 12.7%). Twenty-two (9.7%) of the 229 
patients had a concomitant PD (schizophrenia, n = 9, 41%; depression, n = 10, 45%; 
bipolar disorder, n = 3, 14%), and were defined as the PD group. Four (18.2%) of these 
patients were being treated with a single psychiatric agent while the rest were receiving 
a variety of psychiatric medications. The patients with depression were receiving 
tricyclic or tetracyclic antidepressants or selective serotonin reuptake inhibitors, and 
those with schizophrenia were being treated with typical antipsychotic agents, 
serotonin-dopamine antagonists, multi-acting receptor-targeted antipsychotics agents, or 
dopamine stabilizers. Nine patients (40.9%) in the PD group underwent PEA and the 
others underwent BPA or received medication alone. The patients without a PD were 
enrolled as members of the non-PD group. 
Body weight and body mass index values were significantly higher in the PD 
group than in the non-PD group (62.8 ± 12.7 kg vs. 56.6 ± 10.9 kg, p = 0.014, and 25.3 
± 3.62 vs. 22.2 ± 3.12, p < 0.001, respectively). There was no significant difference in 
age, sex, interval between onset of symptoms and diagnosis of CTEPH, smoking 
history, or WHO functional classification of PH between the two groups. The statistical 
significance of differences between the PD and non-PD groups did not change when the 
data were analyzed according to whether or not PEA had been performed 
(Supplementary Tables 1 and 2). 
 
Pulmonary Hemodynamics  
Table 2 shows the results of the clinical examination in the PD group and the 
non-PD group. There were some missing data points as follows: 4 instances of lupus 
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anticoagulants, 10 of protein C, and 20 of coagulation factor Ⅷ. All the missing data 
were values for patients in the non-PD group. There was no significant difference in the 
level of brain natriuretic peptide or that of any other biomarker between the study 
groups. Right heart catheterization did not reveal any significant between-group 
differences in PAP, CO, or cardiac index.  
 
Exercise Tolerance and Respiratory Function 
The 6MWT results indicated that exercise tolerance was significantly lower in 
the PD group than in the non-PD group (309.5 ± 89.5 m vs. 369.4 ± 97.9 m, p = 0.006). 
Furthermore, spirometry revealed significantly lower %VC and %DLCO in the PD group 
(%VC, 85.5% ± 17.3% vs. 96.0% ± 15.5%, p = 0.003, and %DLCO, 65.4% ± 19.5% vs. 
79.3% ± 17.3%, p < 0.001, respectively). Blood gas analysis while breathing room air 
revealed that the partial pressure of oxygen (PaO2) was significantly lower and partial 
pressure of carbon dioxide (PaCO2) was significantly higher in the PD group than in the 
non-PD group (PaO2, 54.4 ± 8.6 mmHg vs. 59.3 ± 10.7 mmHg, p = 0.039, and PaCO2, 
40.6 ± 4.8 mmHg vs. 37.4 ± 4.1 mmHg, p < 0.001, respectively). In this study, four 
patients in the non-PD group were unable to perform a respiratory function test. Also, 
two in the PD group and 14 in the non-PD group could not perform the 6MWT. 
 
Prognosis  
The median observation period was 66.0 months (95% confidence interval 
55.8–76.3) in the PD group and 72.4 months (95% confidence interval 61.4–83.3) in the 
non-PD group. Thirty-nine patients (17.0%) died during the study period. The cause of 
death was exacerbation of PH in 26 patients and perioperative complications in the 
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other 13. There were no deaths attributable to deterioration of a PD or suicide. There 
were more deaths attributable to CTEPH in the PD group than in the non-PD group 
(7/22 [31.8%] vs. 32/207 [15.5%], p = 0.052). There were also more perioperative 
deaths in the PD group than in the non-PD group (3/9 [33.3%] vs. 10/121 [8.3%], p = 
0.016). There were three deaths in the PD group that were the result of perioperative 
complications after PEA (suspected recurrence of pulmonary thromboembolism [n = 2], 
lung bleeding [n = 1]). In the non-PD group, 10 of the surgically treated patients died of 
perioperative complications (residual PH [n = 2], lung bleeding [n = 4], other [n = 4]). 
Figure 1 shows the patient survival data in the two study groups. Three-year 
survival was significantly worse in the PD group than in the non-PD group (66.1% vs 
89.7%, p = 0.0026). Kaplan-Meier survival estimates for patients with medically and 
surgically treated CTEPH in the study groups are shown in Figures 2 and 3. The patients 
in the PD group who underwent PEA had significantly poorer survival than in the non-
PD group (p < 0.001). However, there was no between-group difference in survival 
when the patients were treated without surgery (p = 0.280). Even when patients treated 
with BPA were excluded from the medically treated group, there was no significant 
difference in survival between the two study groups (p = 0.843; Supplementary Figure 
1). Tables 3 and 4 show the results of the univariate and multivariate analyses in the 
surgically and medically treated patients. In the PEA group, univariate analysis 
identified having a concomitant PD, poor performance on the 6MWT, high PVR, and a 
Jamieson classification of III or IV to be poor prognostic factors. In the multivariate 
analysis, coexistence of a PD was associated with low survival rates (hazard ratio 9.11; 
95% confidence interval 1.85–35.2; p = 0.017). In contrast, there was no significant 
association between having a PD and the prognosis in the medically treated group. 
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Discussion 
To the best of our knowledge, this is the first study to investigate the 
characteristics and prognoses of patients with CTEPH and a concomitant PD. These 
patients had a poorer prognosis than their counterparts without a PD, especially if they 
underwent PEA, and tended to have lower exercise tolerance and poorer pulmonary 
function. 
A PD emerged as a risk factor for mortality in patients with CTEPH, and their 
long-term prognosis was significantly poor, especially if they had undergone PEA. 
Some reports from Japan have suggested an important relationship between CTEPH and 
a psychiatric diagnosis. For example, Suzuki et al. reported that 7% of their patients 
with CTEPH had a diagnosis of schizophrenia,20 as did 3.9% of our patients; both these 
figures are higher than the prevalence of schizophrenia in the general population.21 
Furthermore, Funabashi et al. reported a higher frequency of depression in patients with 
CTEPH.22 Our group has recently identified that a Jamieson classification of III or IV 
and a high PVR were associated with poor survival, although similar survival rates were 
recently observed in patients with CTEPH treated by BPA, PEA, and medication 
between 2009 and 2016.23 The findings of the present study are similar in that a 
Jamieson classification of III or IV was a poor prognostic factor, providing evidence 
that having a PD may be an additional important risk factor for perioperative death in 
patients with CTEPH. 
Several studies have suggested a relationship between antipsychotic or 
antidepressant treatments and thromboembolism,24,25 although studies of long-term 
prognoses in patients with CTEPH have not been performed. In our study, four of seven 
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patients with a PD who died had depression and three had schizophrenia. All seven 
patients had been prescribed multiple medications. However, because of the small 
number of cases, it was not possible to establish whether there was a definite 
relationship between the medication and mortality.  
Furthermore, the poor prognosis of the patients in the PD group despite their 
similar pulmonary hemodynamics at baseline may be associated with a higher risk of 
post-surgical complications. Previous studies in patients undergoing general surgery or 
cardiovascular surgery have suggested that those with a concomitant PD have an 
increased risk of operative complications.26 This increase in risk might be attributable to 
severe comorbidity, a delay in diagnosis and treatment, the adverse effects of 
medication or anesthesia, poor nutrition, and difficulty describing symptoms.26 
Moreover, there are several potential mechanisms via which thromboembolism can 
occur in such patients, including a sedation-related decrease in physical activity, 
induction of antiphospholipid antibodies, and enhancement of platelet aggregation via 
serotonin.27,28 In our study, there were two sudden perioperative deaths in the PD group; 
recurrence of pulmonary embolism was confirmed at autopsy in one patient (who had 
required physical restraint) and was suspected in the other patient. The postoperative 
PVR of patients with PD was higher, although the difference was not statistically 
significant. These results indicate that CTEPH patients with PDs may have some 
potential risks with PEA. Therefore, even if PEA is a curative treatment, the indication 
for surgery in a patient with CTEPH and a concomitant PD needs to be judged carefully. 
However, whether the risk is due to psychotic drugs or PDs themselves could not be 
clarified in this study. We plan to search for detailed risk factors in further examinations 
in the future.  
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In our study, patients with CTEPH and a co-existing PD tended to have 
decreased exercise tolerance and impaired pulmonary function and gas exchange;  
decreased respiratory function and impaired gas exchange diminishes quality of life. 
Also, patients in the PD group were more often smokers than those in the non-PD group 
(45.5% vs. 29.8%, p = 0.230). A previous study also identified an association between 
expiratory spirometry parameters and limitations in activities of daily living in patients 
with schizophrenia.29 In addition, a relationship between obesity and deterioration of 
lung function has been identified in patients with schizophrenia.30 Moreover, in our 
study, patients with CTEPH and a concomitant PD had a significantly higher body mass 
index, which may have caused a decrease in exercise tolerance.  
Further, compliance with medication in patients with PDs is suggested to be 
lower which may make their facilitate a poor prognosis.31 Meanwhile, early detection 
and appropriate treatment is important in patients with CTEPH.32 Therefore, when a 
patient with a PD complains of dyspnea, CTEPH should be included in the differential 
diagnosis, and appropriate therapeutic intervention and careful follow-up is necessary. 
This study had some limitations. First, it had a retrospective single-center 
cohort design and low statistical power; this is inevitable, given that CTEPH is a 
relatively rare disease. Second, the medical and surgical treatment of CTEPH has been 
evolving yearly, so the clinical status of some of the patients in the early years of this 
study may not be comparable with that of those in the later years because of 
improvements in treatment over time. Third, it was difficult to guarantee accurate 
diagnoses of PDs. Even if the diagnosis was provided by a psychiatric specialist, some 
patients were diagnosed at other hospitals and we did not perform screening tests of 
PDs on patients with CTEPH. 
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In summary, a concomitant PD may predict poor survival in patients with 
CTEPH, especially in those who undergo PEA, so the recommendation for PEA should 
be considered carefully. Furthermore, a PD may be associated with reduced exercise 
tolerance and poor respiratory function in these patients. 
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Table 1. Characteristics of patients with chronic thromboembolic pulmonary 
hypertension  
Variable 
PD group 
 (n = 22) 
non-PD group  
(n = 207) 
 p-value 
Age (years) 58.6 ± 13.0 58.7 ± 11.9 0.911 
Sex, n (female / male)  19/3 (86.4%) 141/66 (68.1%) 0.090 
Interval until diagnosis (months) 28.0 ± 29.3 34.8 ± 39.7 0.440 
Smoking (yes / no) 10/12 (45.5%) 61/146 (29.5%) 0.149 
Surgical treatment (yes / no) 9/13 (40.9%) 121/86 (58.5%) 0.173 
Height (m) 1.57 ± 0.097 1.60 ± 0.098 0.185 
Weight (kg) 62.8 ± 12.7 56.6 ± 10.9 0.027 
Body mass index 25.3 ± 3.62 22.2 ± 3.12 < 0.001 
WHO classification 2.77 ± 0.53 2.66 ± 0.63 0.407 
Diabetes mellitus 0/22 (0.0%) 12/207 (5.8%) 0.114 
COPD 5/17 (22.7%) 48/157 (23.4%) 0.942 
The data are presented as the mean ± standard deviation. The bold letters indicate significant correlations. 
COPD, chronic obstructive pulmonary disease; PD, psychiatric disorder; WHO, World Health 
Organization 
 
Table 2. Characteristics of patients with chronic thromboembolic pulmonary 
hypertension  
Parameter 
PD group 
 (n = 22) 
non-PD group  
(n = 207) 
 p-value 
Blood test    
BNP (pg/mL) 171.8 ± 285.4 212.2 ± 293.0 0.709 
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D-dimer (µg/mL) 0.50 ± 0.65 1.14 ± 1.73 0.089 
Coagulation factor VIII (%) 158.4 ± 85.6 161.9 ± 101.3 0.876 
Fibrinogen (mg/dL) 292.2 ± 76.5 299.3 ± 74.9 0.677 
Protein C (%) 56.5 ± 24.1 62.9 ± 25.5 0.260 
Lupus anticoagulant (+ / −) 7/15 (31.8%) 41/161 (20.3%) 0.271 
Right heart catheterization     
Mean PAP (mmHg) 45.5 ± 10.6 43.8 ± 11.6 0.423 
CO (L / min) 4.27 ± 1.36 4.15 ± 1.13 0.911 
Cardiac index  2.77 ± 0.63 2.65 ± 0.67 0.113 
PVR (Wood units) 8.69 ± 4.07 9.37 ± 4.43 0.587 
PVR one month after PEA 
(Wood units) 
5.53±3.54 3.82 ± 2.24 0.083 
PaO2 (mmHg) 54.4 ± 8.6 59.3 ± 10.7 0.0498 
PaCO2 (mmHg) 40.6 ± 4.8 37.4 ± 4.1 0.005 
PvO2 (mmHg) 32.93 ± 3.80 33.26 ± 4.05 0.865 
AaDO2 (mmHg) 47.2 ± 9.8 45.6 ± 11.1 0.507 
Respiratory function tests    
6-minute walk distance (m) 309.5 ± 89.5 369.4 ± 97.9 0.005 
Modified Borg scale 4.36 ± 3.17 3.59 ± 2.24 0.165 
Percent vital capacity (%) 85.5 ± 17.3 96.0 ± 15.5 0.020 
FEV1 (%) 75.7 ± 8.33 75.3 ± 8.20 0.810 
DLCO (%) 65.4 ± 19.5 79.3 ± 17.3 0.022 
DLCO / VA 3.85 ± 0.99 4.03 ± 0.84 0.362 
The data are presented as the mean ± standard deviation. The bold letters indicate significant correlations. 
 22 
 
BNP, brain natriuretic peptide; CO, cardiac output; FEV1, forced expiratory volume in 1 second; PD, 
psychiatric disorder; PVR, pulmonary vascular resistance; DLCO, diffusing capacity for carbon dioxide; 
VA, alveolar ventilation, PaO2, partial pressure of oxygen; PaCO2, partial pressure of carbon dioxide; 
PvO2, venous oxygen tension; AaDO2, alveolar-arterial oxygen gradient. 
 
Table 3. Univariate and multivariate analyses of prognostic factors in patients with 
chronic thromboembolic pulmonary hypertension who had a psychiatric disorder and 
underwent pulmonary endarterectomy (n = 130) 
Parameter 
Univariate Multivariate 
Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value 
Psychiatric disorder (+ / −) 6.17 (1.72–17.6) 0.002 8.39 (1.93–31.8) 0.0064 
Sex (female / male)  1.01 (0.41–2.73) NS   
Age (years)* 0.995 (0.96–1.04) NS 0.996 (0.95–1.04) NS 
Body mass index (kg / m2)* 1.06 (0.92–1.19) NS   
Smoking (+ / −) 1.44 (0.56-3.56) NS   
Diabetes mellitus (+ / −) 1.13 (0.062-5.49) NS   
COPD (+ / −) 1.73 (0.58-7.44) NS   
%VC (%)* 0.087 (0.0079-0.95) 0.046 0.971 (0.934-1.008) NS 
%DLCO (%)* 0.99 (0.96–1.01) NS   
mPAP (mmHg)* 1.04 (0.99–1.08) 0.085   
Cardiac index (mL/min/m2)* 0.60 (0.27–1.19) NS   
PVR (Wood units)* 1.11 (1.00–1.23) 0.037 1.12 (0.95–1.31) NS 
6-minute walk test (m)* 0.99 (0.987–0.997) 0.002 0.999 (0.993–1.006) NS 
PaO2 (mmHg)* 1.03 (0.98–1.08) NS   
Jamieson classification III–IV (vs. I–II) 3.67 (1.17–9.88) 0.028 4.45 (1.29–13.7) 0.021 
WHO functional class 3–4 (vs.1–2) 2.54 (0.84–10.9) NS 1.89 (0.52–9.03) NS 
Selective pulmonary vasodilators (+ / −)  0.34 (0.053–1.20) 0.099 0.34 (0.06–1.31) NS 
 23 
 
The data are presented as the mean ± standard deviation. *Per-unit increase. p < 0.05. Significant 
differences between patients with CTEPH who had and did not have a psychiatric disorder were 
determined using univariate and multivariate regression analyses. The bold letters indicate significant 
correlations. CI, confidence interval; COPD, chronic obstructive pulmonary; DLCO, diffusing capacity for 
carbon monoxide; mPAP, mean pulmonary arterial pressure; NS, not statistically significant(p ≥0.05); 
PaO2, partial pressure of oxygen; PVR, pulmonary vascular resistance; VA, alveolar ventilation; VC, vital 
capacity; WHO, World Health Organization  
 
Table 4. Univariate and multivariate analyses of prognostic factors in patients with 
chronic thromboembolic pulmonary hypertension who had a psychiatric disorder and 
did not undergo pulmonary endarterectomy (n = 99) 
Parameter 
Univariate Multivariate 
Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value 
Psychiatric disorder (+ / −)  2.00 (0.45–6.42) 0.32 2.61 (0.36–12.3) NS 
Sex (female / male)  0.87 (0.34–2.69) NS   
Age (years)* 1.004 (0.97–1.04) NS 0.99 (0.95–1.03) NS 
Body mass index (kg/m2)* 0.92 (0.77–1.08) NS   
Smoking (+ / −) 1.20 (0.43-3.03) NS   
Diabetes mellitus (+ / −) 6.42 (1.82-17.8) 0.0065   
COPD (+ / −) 1.17 (0.42-4.16) NS   
% VC (%)* 0.94 (0.061-29.7) NS   
% DLCO (%)* 0.997 (0.98–1.02) NS   
mPAP (mmHg)* 1.04 (0.99–1.08) 0.063   
Cardiac index (mL/min/m2)* 0.26 (0.092–0.63) 0.0060   
PVR (Wood units)* 1.18 (1.08–1.29) < 0.001   
6-minute walk test (m)* 0.992 (0.987–0.997) 0.0032 0.99 (0.987–0.998) 0.012 
PaO2 (mmHg)* 0.94 (0.89–0.98) 0.0090 0.94(0.88–1.001) NS 
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Central disease score 2–4 (vs.0–1) 1.47 (0.47–3.80) NS 1.13 (0.29–3.63) NS 
WHO functional class 3–4 (vs. 1–2) 3.11 (0.93–10.0) NS   
Selective pulmonary vasodilators 
 (+ / −) 
0.47 (0.18–1.18) 0.12 0.29 (0.083–0.88) 0.029 
The data are presented as the mean ± standard deviation. *Per-unit increase. p < 0.05. Significant 
differences between patients with chronic thromboembolic pulmonary hypertension who did and did not 
have a psychiatric disorder were determined using univariate and multivariate regression analyses. The 
bold letters indicate significant correlations CI, confidence interval; DLCO, diffusing capacity for carbon 
monoxide; mPAP, mean pulmonary arterial pressure; NS, not statistically significant; PVR, pulmonary 
vascular resistance; VA, alveolar ventilation; VC, vital capacity; WHO, World Health Organization 
 
Supplementary Table 1. Characteristics of patients with chronic thromboembolic 
pulmonary hypertension who underwent pulmonary endarterectomy (n=130) 
Variable 
PD group 
(n=9) 
non-PD group 
(n=121) 
p-value 
Age (years) 58.8 ± 12.2 57.7 ± 10.8 0.386 
Sex, n (female/male)  8/1 75/46 0.155 
Interval until diagnosis (months) 29.3 ± 24.1 39.7 ± 45.6 0.524 
Smoking (yes/no) 5/4 39/82 0.154 
Height (m) 1.56 ± 0.072 1.60 ± 0.098 0.221 
Weight (kg) 63.1 ± 15.4 57.6 ± 11.0 0.158 
Body mass index 25.6 ± 4.36 22.3 ± 3.15 0.0039 
WHO classification 2.89 ± 0.60 2.72 ± 0.62 0.441 
The data are presented as the mean ± standard deviation. The bold letters indicate significant correlations.  
PD, psychiatric disorder; WHO, World Health Organization  
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Supplementary Table 2. Characteristics of patients with chronic thromboembolic 
pulmonary hypertension who received balloon pulmonary angioplasty or medication 
(n=99) 
Variable 
PD group 
(n=13) 
non-PD group 
(n=86) 
p-value 
Age (years) 58.5 ± 14.1 60.0 ± 13.2 0.709 
Sex, n (female/male)  11/2 66/20 0.723 
Interval until diagnosis (months) 29.2 ± 33.3 28.8 ± 28.5 0.964 
Smoking (yes/no) 4/9 22/64 0.692 
Height (m) 1.58 ± 0.11 1.58 ± 0.097 0.807 
Weight (kg) 62.5 ± 11.0 55.3 ± 10.6 0.024 
Body mass index 25.1 ± 3.19 22.0 ± 3.07 <0.001 
WHO classification 2.69 ± 0.48 2.56 ± 0.63 0.468 
The data are presented as the mean ± standard deviation. The bold letters indicate significant correlations. 
PD, psychiatric disorder; WHO, World Health Organization  
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Figure legends 
 
Figure 1.  
Kaplan-Meier survival curves for patients with chronic thromboembolic pulmonary 
hypertension classified according to the presence or absence of a concomitant 
psychiatric disorder. Survival was poorer in patients with a psychiatric disorder than in 
those without (p = 0.0026, log-rank test). CTEPH, chronic thromboembolic pulmonary 
hypertension. 
 
Figure 2.  
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Kaplan-Meier survival curves for patients with medically treated chronic 
thromboembolic pulmonary hypertension with and without a concomitant psychiatric 
disorder. Survival tended to poorer in the patients with a psychiatric disorder but not to 
the point of statistical significance (p = 0.280, log-rank test). 
 
Figure 3.  
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Kaplan-Meier survival curves for patients with surgically treated chronic 
thromboembolic pulmonary hypertension with and without a concomitant psychiatric 
disorder. Survival was significantly poorer in the patients with a psychiatric disorder (p 
< 0.001, log-rank test). 
 
Supplementary Figure 1. 
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Kaplan-Meier survival curves for patients with chronic thromboembolic pulmonary 
hypertension with and without a concomitant psychiatric disorder who received only 
pulmonary vasodilators without pulmonary endarterectomy or balloon pulmonary 
angioplasty. There was no significant difference between the two groups (p=0.843, log-
rank test). PD, psychiatric disorder 
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